ODT - Odonate Therapeutics: Making Taxanes Orally Available
Odonate Therapeutics (ODT) is led by Kevin Tang, a successful serial biopharma entrepreneur who has made billions in the industry, most notably from the sale of Ardea Biosciences, which he founded, to AstraZeneca (AZN) for $1bn. Mr. Tang owns over 50% of Odonate. ODT focuses on a single drug, tesetaxel, an improved oral version of commonly used chemotherapy agents taxanes, which targets HER2- HR+ breast cancer in patients.
Despite considerable progress in developing other medicine forms, chemotherapy remains a mainstay of metastatic breast cancer ((MBC)) treatment. Taxanes - paclitaxel, nab-paclitaxel, and docetaxel -